New study investigates brain fog after CAR-T and bispecific antibody therapies
NCT ID NCT07558057
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will follow 225 blood cancer patients receiving CAR-T therapy, bispecific antibodies, or high-dose chemotherapy with stem cell transplant. Researchers will test memory, attention, and thinking skills before treatment and up to 3 years after. The goal is to understand how often cognitive problems occur and how they affect quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this study could lead to better monitoring and support for cognitive side effects in patients receiving advanced immunotherapies for blood cancers.
What could go wrong
This is an observational study, not a treatment trial. It will not test any new therapy, and results may not apply to all patients or healthcare settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aarhus University Hospital
Aarhus, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••